Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: Correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials

被引:47
|
作者
Lassen, Pernille [1 ]
Overgaard, Jens [1 ]
Eriksen, Jesper Grau [2 ]
机构
[1] Aarhus Univ Hosp, Dept Expt Clin Oncol, Aarhus, Denmark
[2] Odense Univ Hosp, Dept Oncol, DK-5000 Odense C, Denmark
关键词
EGFR; HPV; p16; HNSCC; Radiotherapy; SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; NECK-CANCER; HUMAN-PAPILLOMAVIRUS; TUMOR DIFFERENTIATION; SUPRAGLOTTIC LARYNX; TREATMENT TIME; HEAD; SURVIVAL; SMOKING;
D O I
10.1016/j.radonc.2013.08.036
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: EGFR and HPV-associated p16 are among the most investigated biomarkers in head and neck cancer. The aim was to investigate the correlation and interaction between these two markers and to evaluate their potential prognostic significance when combined. Materials and methods: 336 Oropharyngeal carcinomas treated with primary radiotherapy (66-68 Gy, 2 fx/day, 10-12 Gy/week) and with known EGFR/p16-status estimated semiquantitatively by immunohistochemistry were included in the study. Data were evaluated by EGFR-expression (high/low) and p16-status (positive/negative) consequently dividing tumours into four groups by combination of the biomarkers. Patient/tumour characteristics and complete 5-year follow-up were available. Results: Low EGFR-expression was significantly more common in p16-positive tumours compared to p16-negative, p < 0.0001. p16 positivity showed a strong prognostic impact (p < 0.0001, HR = 0.22 [0.13-0.38]), whereas EGFR was a weak prognostic marker when local control was used as endpoint (p = 0.03, HR = 0.53 [0.29-0.94]). Combination of EGFR/p16 did not add significant information to p16 alone and by multivariable analysis only p16 showed significant prognostic information for all evaluated endpoints. Conclusions: Both EGFR and p16 bear prognostic information in oropharyngeal cancer, although p16 is, by far, the strongest prognostic factor. The markers seem to be correlated and this might have influence when evaluating the effect of EGFR inhibition in oropharyngeal tumours. (C) 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 108 (2013) 489-494
引用
收藏
页码:489 / 494
页数:6
相关论文
共 29 条
  • [21] Effect of HPV-Associated p16INK4A Expression on Response to Radiotherapy and Survival in Squamous Cell Carcinoma of the Head and Neck
    Lassen, Pernille
    Eriksen, Jesper G.
    Hamilton-Dutoit, Stephen
    Tramm, Trine
    Alsner, Jan
    Overgaard, Jens
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) : 1992 - 1998
  • [22] p16 expression in cutaneous squamous cell carcinoma of the head and neck is not associated with integration of high risk HPV DNA or prognosis
    Satgunaseelan, Laveniya
    Chia, Noel
    Suh, Hyerim
    Virk, Sohaib
    Ashford, Bruce
    Lum, Trina
    Ranson, Marie
    Clark, Jonathan
    Gupta, Ruta
    PATHOLOGY, 2017, 49 (05) : 494 - 498
  • [23] Expression of p16, p53, and TLR9 in HPV-Associated Head and Neck Squamous Cell Carcinoma: Clinicopathological Correlations and Potential Prognostic Significance
    Wang, Shu
    Zhuang, Xibing
    Gao, Caixia
    Qiao, Tiankui
    ONCOTARGETS AND THERAPY, 2021, 14 : 867 - 877
  • [24] Differential expression of EGFR, HER2, P16, and high-risk (hr) HPV status in oropharyngeal (Or) and oral cavity (OC) squamous cell carcinoma (SCC).
    Sudaka, Anne
    Saada, Esma
    Natale, Romain
    Poissonnet, Gilles
    Benezery, Karen
    Bozec, Alexandre
    Hebert, Christophe
    Dassonville, Olivier
    Peyrade, Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] High Expression of PRMT5 and Cyclin D1 Is Associated With Poor Outcome in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Patients and Is Inversely Associated With p16 Status
    Kumar, B.
    Cipolla, M. J.
    Arradaza, N.
    Wakely, P. E.
    Yan, F.
    Schmitt, A.
    Kumar, P.
    Baiocchi, R. A.
    Teknos, T. N.
    Old, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 513 - 514
  • [26] Identification of good and poor prognosis HPV associated oropharyngeal cancer based on CD103 immune cell expression in patients treated with cetuximab and radiotherapy on TROG 12.01 and De-ESCALaTE randomized trials.
    Rischin, Danny
    Mehanna, Hisham Mohamed
    Young, Richard J.
    Bressel, Mathias
    Dunn, Janet
    Corry, June
    Fulton-Lieuw, Tessa
    Iqbal, Gulnaz
    Kenny, Lizbeth M.
    Porceddu, Sandro
    Wratten, Christopher
    Robinson, Max
    Solomon, Benjamin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] High-Risk HPV E6/E7 mRNA Detection by a Novel In-Situ Hybridization Assay Strongly Correlates with p16 Expression and Patient Outcomes in Oropharyngeal Squamous Cell Carcinoma
    Ukpo, O. C.
    Flanagan, J.
    Luo, Y.
    Ma, X-J
    Lewis, J. S.
    MODERN PATHOLOGY, 2011, 24 : 283A - 284A
  • [28] High-Risk HPV E6/E7 mRNA Detection by a Novel In-Situ Hybridization Assay Strongly Correlates with p16 Expression and Patient Outcomes in Oropharyngeal Squamous Cell Carcinoma
    Ukpo, O. C.
    Flanagan, J.
    Luo, Y.
    Ma, X-J
    Lewis, J. S.
    LABORATORY INVESTIGATION, 2011, 91 : 283A - 284A
  • [29] Impact of p16 expression on induction taxotere-cisplatin-5 FU (TPF) followed by cetuximab-radiotherapy in N2b-N3 head and neck squamous cell carcinoma (HNSCC): Results of GORTEC 2007-02 phase III randomized trial.
    Tao, Yungan
    Geoffrois, Lionnel
    Martin, Laurent
    De Raucourt, Dominique
    Miny, Joelle
    Maingon, Philippe
    Lafond, Cedrik
    Tuchais, Claude
    Sire, Christian
    Babin, Emmanuel
    Coutte, Alexandre
    Rolland, Frederic
    Girard-Calais, Marie-Helene
    Casiraghi, Odile
    Garaud, Pascal
    Bourhis, Jean
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35